Canada Authorizes new Epilepsy Treatment

According to recent reports, Health Canada has authorized Eisai Limited’s drug FYCOMPA (perampanel) for use as a treatment option for partial-onset seizures in adults who are having difficulties with other treatments.

FYCOMPA is considered a first-in-class treatment that targets post-synaptic AMPA glutamate receptors, which is considered a new way to approach seizure prevention. Now that Health Canada has authorized the drug’s use, it is worth noting that the decision was mostly due to the results of three Phase III studies. These were multi-center, randomized, double-blind, placebo-controlled, parallel group studies that looked into the efficacy and safety of FYCOMPA in comparison to a placebo that was given. The results of the studies showed that FYCOMPA worked in reducing the onset of seizures in the patients who had partial-onset seizures regardless of whether they had secondarily-generalized seizures.

“FYCOMPA represents an innovative approach in the treatment of epilepsy and a much-needed option for Canadian patients and physicians,” says Dr. Neelan Pillay, Clinical Professor, Director Adult Epilepsy Program, EEG and Evoked Potentials, Department of Clinical Neurosciences, Foothills Medical Centre. “When added to their current treatment regimen, FYCOMPA is shown to significantly reduce seizures in patients.”

“Health Canada’s authorization of FYCOMPA marks another important milestone for Canadian epilepsy patients with partial-onset seizures who now have a new option that is proven to control their seizures,” says Oliver Technow, President and General Manager, Eisai Limited. “Eisai’s human healthcare philosophy centers around improving the health and quality of life for patients and their families and we are committed to improving these lives by providing innovative therapies that can have a positive impact.”

Other anti-seizure medications on the market are already used in Canada but are linked to serious side effects. One of those medications is Topamax. Topamax has been linked to an increased risk of suicide and suicidal thoughts as well as birth defects in women whose babies are exposed to the drug in-utero. Some of those birth defects linked to Topamax use during pregnancy include cleft lips, cleft palates, genital defects and other birth malformations.

If your baby was born with birth defects after in-utero exposure to Topamax, contact attorney Greg Jones today for a free consultation. I am experienced at fighting Topamax lawsuits and may be able to help you recover money for your child’s injuries.

Share this article

You May Also Like

All Rights Reserved 2016